Ocean Biomedical (“the Company”), (NASDAQ: OCEA) a next-generation
biopharma company, today announced it will visit the Nasdaq
MarketSite in Times Square to ring the Opening Bell on Thursday,
February 16, 2023, from 9:15 a.m. to 9:30 a.m. ET. Leading the
iconic ceremony will be Dr. Chirinjeev Kathuria, Ocean Biomedical
co-founder and Executive Chairman of the Board of Directors. The
company’s common stock and warrants are listed on Nasdaq under the
symbols “OCEA” and “OCEAW,” respectively.
Leadership Commentary
“Today is a landmark moment in the young life of
Ocean Biomedical,” said Dr. Chirinjeev Kathuria, Ocean Biomedical
co-founder and Executive Chairman of the Board of Directors. “Our
listing on the Nasdaq will propel us forward to finance our future
of better medicines to meet unmet medical needs not only in the US,
but globally. My fellow co-founders and I created the Company with
a single aim: to offer the world recourse against deadly diseases,
including Malaria, numerous cancers and pulmonary fibrosis.
Together, our leading researchers and institutional partners are
primed to turn that vision into reality.”
“Ocean Biomedical offers a brighter view of
medicine’s future,” said Suren Ajjarapu, Chairman and CEO of
Aesther Healthcare Acquisition Corp. and Ocean Biomedical Board
Member. “Our newly earned status as a publicly traded company
serves to legitimize that vision. I’m looking forward to
celebrating on the trading floor our work thus far and all that is
to come.”
Ocean Is Addressing Areas of Great Unmet
Need
Built on an innovative business model, Ocean
Biomedical bridges the ‘bench-to-bedside’ gap by accelerating the
commercialization of innovative assets from research universities
and medical centers. That involves elevating the efforts of
scientists at these institutions to ensure their discoveries
advance through discovery to clinical trials, eventually reaching
the hands of doctors and patients who need them. Ocean Biomedical’s
core portfolio, built from relationships with these leading
institutions, is currently focused in three critical areas:
oncology, pulmonary fibrosis, and infectious disease. Each include
new target discoveries that will enable first-in-class drug and
vaccine candidates, developed through past and ongoing grants
totaling $123.9 million. All three represent large markets with
tremendous unmet medical needs.
AdvisorsCohen & Company
Capital Markets serves as lead capital markets advisor along with
EF Hutton, division of Benchmark Investments, LLC to Aesther
Healthcare Acquisition Corp. Nelson Mullins Riley & Scarborough
LLP serves as legal counsel to Aesther Healthcare Acquisition Corp.
and Malone Bailey, LLP serves as auditors to Aesther Healthcare
Acquisition Corp. Dykema Gossett PLLC serves as legal counsel to
Ocean Biomedical, Inc. and Deloitte & Touche LLP serves as
auditors to Ocean Biomedical, Inc.
About Ocean
Biomedical
Ocean Biomedical, Inc. is a Providence, Rhode
Island-based biopharma company with an innovative business model
that accelerates the development and commercialization of
scientifically compelling assets from research universities and
medical centers. Ocean Biomedical deploys the funding and expertise
to move new therapeutic candidates efficiently from the laboratory
to the clinic, to the world. Ocean Biomedical is currently
developing five promising discoveries that have the potential to
achieve life-changing outcomes in lung cancer, brain cancer,
pulmonary fibrosis, and the prevention and treatment of malaria.
The Ocean Biomedical team is working on solving some of the world’s
toughest problems, for the people who need it most.
To learn more, visit www.oceanbiomedical.com
Forward-Looking Statements
The information included herein and in any oral
statements made in connection herewith include “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the United States Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “estimate,” “plan,” “project,” “forecast,” “intend,”
“will,” “expect,” “anticipate,” “believe,” “seek,” “target” or
other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters, although
not all forward-looking statements contain such identifying words.
These forward-looking statements include, but are not limited to,
statements regarding estimates and forecasts of financial and
performance metrics and expectations. These statements are based on
various assumptions, whether or not identified herein, and on the
current expectations of the Company’s management and are not
predictions of actual performance. These forward-looking statements
are provided for illustrative purposes only and are not intended to
serve as, and must not be relied on by any investor as, a
guarantee, an assurance, a prediction or a definitive statement of
fact or probability. Actual events and circumstances are difficult
or impossible to predict and will differ from assumptions.
Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. These forward-looking
statements are not guarantees of future performance, conditions or
results, and involve a number of known and unknown risks,
uncertainties, assumptions and other important factors, many of
which are outside the control of the Company that could cause
actual results or outcomes to differ materially from those
discussed in the forward-looking statements. Important factors,
among others, that may affect actual results or outcomes include
(i) the outcome of any legal proceedings that may be instituted
against the Company; (ii) changes in the markets in which the
Company competes, including with respect to its competitive
landscape, technology evolution, or regulatory changes; (iii)
changes in domestic and global general economic conditions; (iv)
risk that the Company may not be able to execute its growth
strategies; (v) risks related to the ongoing COVID-19 pandemic and
response, including supply chain disruptions; (vi) risk that the
Company may not be able to develop and maintain effective internal
controls; (vii) the risk that the Company may fail to keep pace
with rapid technological developments to provide new and innovative
products and services or make substantial investments in
unsuccessful new products and services; (viii) the ability to
develop, license or acquire new therapeutics; (ix) the risk that
the Company will need to raise additional capital to execute its
business plan, which may not be available on acceptable terms or at
all; (x) the risk that the Company experiences difficulties in
managing its growth and expanding operations; (xi) the risk of
product liability or regulatory lawsuits or proceedings relating to
the Company’s business; (xii) the risk of cyber security or foreign
exchange losses; (xiii) the risk that the Company is unable to
secure or protect its intellectual property
The foregoing list of factors is not exhaustive.
You should carefully consider the foregoing factors and the other
risks and uncertainties that are described in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and its
Quarterly Report on Form 10-Q for the quarter ended September 30,
2022, and which are described in the “Risk Factors” section of the
Company’s definitive proxy statement filed by the Company on
January 12, 2023, and other documents to be filed by the Company
from time to time with the SEC and which are and will be available
at www.sec.gov. These filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, These forward-looking statements should
not be relied upon as representing the Company’s assessments as of
any date subsequent to the date of this filing. Accordingly, undue
reliance should not be placed upon the forward-looking
statements.
Investor ContactEmail:
IR@aestherhealthcarespac.com
Media ContactSean LeousICR WestwickePhone:
+1.646.866.4012Email: Sean.Leous@westwicke.com
Grafico Azioni Ocean Biomedical (NASDAQ:OCEAW)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Ocean Biomedical (NASDAQ:OCEAW)
Storico
Da Ott 2023 a Ott 2024